irinotecan has been researched along with nutlin-3a in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ding, K; Kang, S; McEachern, D; Miller, R; Nikolovska-Coleska, Z; Qin, D; Qiu, S; Shangary, S; Wang, G; Wang, S; Yang, D; Yu, S | 1 |
| Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Wu, Y; Yao, J; Zhang, W; Zhang, Y; Zhu, L; Zhuang, C | 1 |
| Abrams, SL; Akula, SM; Bueno-Silva, B; Candido, S; Cervello, M; Cocco, L; de Alencar, SM; Follo, MY; Gizak, A; Lertpiriyapong, K; Libra, M; Lin, HL; Lombardi, P; Mao, W; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Rakus, D; Ratti, S; Rosalen, PL; Steelman, LS | 1 |
| Chi, SW; Lee, B; Lee, SO; Min, JA; Nashed, A; Yi, GS; Yoo, JC | 1 |
| Gunasegaran, B; Neilsen, PM; Smid, SD | 1 |
| Han, B; Hino, O; Ishimine, M; Kajino, K; Kobayashi, T; Lee-Okada, HC; Nishikawa, K; Orita, H; Takagaki, T; Yokomizo, T | 1 |
6 other study(ies) available for irinotecan and nutlin-3a
| Article | Year |
|---|---|
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Bone Neoplasms; Cell Line, Tumor; Drug Design; HCT116 Cells; Humans; Indoles; Mice; Morpholines; Osteosarcoma; Piperazines; Proto-Oncogene Proteins c-mdm2; Rats; Spiro Compounds; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2009 |
Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Neoplasms; Nuclear Proteins; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrrolidinones; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2012 |
Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Dietary Supplements; Humans; Imidazoles; Irinotecan; Oxaliplatin; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Tumor Suppressor Protein p53 | 2019 |
A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
Topics: Apoptosis; Bcl-2-Like Protein 11; bcl-X Protein; Binding Sites; Biphenyl Compounds; Cell Cycle Checkpoints; Cell Proliferation; DNA Topoisomerases, Type I; HCT116 Cells; Humans; Imidazoles; Irinotecan; Models, Molecular; Nitrophenols; Nuclear Magnetic Resonance, Biomolecular; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Sulfonamides; Tumor Suppressor Protein p53 | 2019 |
P53 activation suppresses irinotecan metabolite SN-38-induced cell damage in non-malignant but not malignant epithelial colonic cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Colon; Colorectal Neoplasms; Epithelial Cells; Humans; Imidazoles; Irinotecan; Piperazines; Tumor Suppressor Protein p53 | 2020 |
Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboxylesterase; Cell Death; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Irinotecan; Mesothelioma; Mutagens; Piperazines; Tumor Suppressor Protein p53 | 2020 |